Clinical Trial Update: DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC [Phase 3]

View source ↗

Summary

Phase 3 trial DAHANCA 19 evaluates the EGFR inhibitor zalutumumab for outcomes after curative radiotherapy in head and neck cancer. The document discusses the p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Zalutumumab (zalutumumab)

Snippet

Sponsor: Danish Head and Neck Cancer Group | Conditions: Cancer of the Head and Neck | Phase 3 | Status: COMPLETED